Epigenex Health helps those accountable for population health improvements to prevent, mitigate, and manage cardiometabolic diseases (CMDs) using an epigenetically informed set of protocols and toolkits collectively known as Cardiometabolic Care.
Developed by three health industry pioneers, Epigenex Health Cardiometabolic Care serves population health decision-makers, care teams, and practice-based researchers.
The Company's founders include:
Delivering new science, new systems, and new outcomes, Cardiometabolic Care includes three easy-to-adopt primary-care practice (PCP) protocols, three clinical-specialty protocols, and three practice-transformation toolkits--all supported by patient wraparound services.
The primary-care protocols target
The clinical-specialty protocols target
The practice-transformation toolkits include
The protocols and toolkits dovetail with leading chronic condition management strategies to more reliably, efficiently, and effectively prevent, mitigate, and resolve cardiometabolic diseases (CMDs).
Cardiometabolic Care is an essential solution set under the healthcare industry's volume-to-value (V2V) transition. The protocols and toolkits generate unprecedented improvements in economic, clinical, and humanistic outcomes (ECHOs).
Three cardiometabolic population health management initiatives underscored the ability of Cardiometabolic Care protocols and toolkits to support the elusive Triple/Quadruple Aim.
In each of these practice-based research programs, epigenetically informed CMD protocols and practice transformation toolkits
The practice-based research populations included:
Backed by primary and secondary research, Cardiometabolic Care‘s groundbreaking protocols and toolkits are safe, efficacious, and cost-effective.
Focusing in an unprecedented way on the epigenetic influences of a broad range of cardiometabolic stressors, Cardiometabolic Care (1) counters the influence of these dangerous stressors upstream and (2) mitigates their epigenetic effects downstream--targeting a largely overlooked stressor-related molecular signaling pathway that is remarkably shared by more than two-dozen chronic conditions.
By targeting this epigenetics-related metabolic common denominator—and by connecting the scientific dots between a range of life stressors and this adverse metabolic cascade—Cardiometabolic Care‘s unified protocols and toolkits are able to:
Count on us to help you make meaningful progress around…
Lifestyle and Behavior Challenges
Ischemic Vascular Disease
While our unified, stressor-mitigating upstream protocols and toolkits and our unified, disease-mitigating downstream protocols and toolkits are gaining mainstream buy-in, we continue to welcome partnerships with progressive health industry stakeholders committed to measurably reducing the incidence, prevalence, and cost of cardiometabolic conditions.
In an era of performance, outcomes, and impact accountability, our protocols and toolkits are a "must have." They offer an unprecedented return on investment (ROI) to organizations that carry non-transferrable financial and human capital risks in relation to cardiometabolic diseases (CMDs).
Organizations that benefit most include:
Reflecting on prior studies using optimal medical therapy (OMT), our shared goal with pioneering partners is to further document the 360-degree impact associated with the application of our molecular medical management (MMM) and patient wraparound services on heart attacks and other high-cost, high-risk conditions.
For example, we seek to document cost savings beyond the Kaiser Permanente's already-demonstrated $21,900 per patient per year (PPPY) savings threshold for optimal medical therapy (OMT), with greater than tenfold reductions in mortality.
Count on us to empower primary care practices (PCPs) and performance-accountable, outcomes-accountable, and impact-accountable specialty practices while reducing the clinical, administrative, and financial risks associated with cardiometabolic diseases (CMDs) and other chronic conditions.
Together, we can reduce the incidence, prevalence, and cost of cardiometabolic disease (CMD).
Copyright © 2019 Epigenex Health, Inc. All Rights Reserved.